Real-world feasibility of first-line palbociclib for hormone receptor-positive HER2-negative locally advanced/metastatic breast cancer in women aged 70 years and older – final results of the endocrine-sensitive cohort in the French prospective non-interventional PalomAGE study
Abstract
Background Breast cancer (BC) is the most commonly diagnosed cancer among women, with 30% of cases occurring at age ≥70 years (70+). Because patients 70+ are underrepresented in BC clinical trials, real-world data may help fill treatment knowledge gaps for this population. Patients and methods PalomAGE is a French observational, multicentre, prospective study assessing the real-world feasibility of ET + palbociclib in women 70+ with hormonal receptor-positive/HER2-negative (/HER+/HER2-) locally advanced/metastatic BC (ABC). The primary endpoint was palbociclib permanent discontinuation rate at 18 months. Secondary endpoints included time to treatment failure (TTF), real-world progression-free survival (rwPFS), health-related quality of life (HRQoL) and geriatric status (G8 and G-CODE). Here, we report results from the endocrine-sensitive cohort, using ET + palbociclib as first-line treatment. Results From October 2018 through December 2020, 412 patients were enrolled. Of these, 382 received ≥1 cycle of palbociclib. With a median follow-up of 25.2 months, the 18-month palbociclib permanent discontinuation rate was 41%. The median TTF and rwPFS were 23.0 and 30.4 months, respectively. Palbociclib dose reduction and permanent discontinuation due to adverse events occurred in 35% and 11% of patients, respectively. There were no new safety signals and HRQoL remained stable throughout treatment. An altered G8 (≤14/17) at baseline was an independent factor for palbociclib discontinuation by multivariate analysis. Conclusion This analysis showed that first-line ET + palbociclib is feasible, well-tolerated and maintains HRQoL in women 70+ with endocrine-sensitive HR+/HER2- ABC, consistent with results from the general adult population. The G8 tool may help identify vulnerable older patients needing further geriatric assessment.
Related
- SERENA-6 interpretation and clinical implications: intercepting endocrine resistance in metastatic breast cancer
- Early systemic intervention for vitiligo: A prospective bicentric interventional study
- Safety and Feasibility of Infusing Ex Vivo Expanded Allogeneic Canine Natural Killer Cells for the Treatment of Metastatic Solid Tumours
- Point-of-care hearing screening using consumer wireless earbuds in patients with USH2A-associated retinal disease: a prospective pilot feasibility study
- Feasibility and performance of eye movement perimetry for glaucoma triage in Tanzania: A prospective cross-sectional study in a real-world setting
BibTeX
@article{carola2026realworld,
title = {{Real-world feasibility of first-line palbociclib for hormone receptor-positive HER2-negative locally advanced/metastatic breast cancer in women aged 70 years and older – final results of the endocrine-sensitive cohort in the French prospective non-interventional PalomAGE study}},
author = {E. Carola and P. Caillet and C. Falandry and L. Tassy and E. Paillaud and M. Pulido and G. Rochette de Lempdes and M. Bringuier and N. Jovenin and A. Boudrant and J. Grosjean and C. Chakiba-Brugere and O. Guillem and A C Hardy Bessard and H. Orfeuvre and E. Legouffe and Y. Brault and C. Chen and A. Coumert and M. Decrop and F. Bouteiller and E. Brain},
journal = {The Breast},
year = {2026},
month = nov,
doi = {10.1016/j.breast.2026.104879},
url = {https://hal.science/hal-05866217v1},
note = {CC BY-NC-ND 4.0},
}
RIS
TY - JOUR
TI - Real-world feasibility of first-line palbociclib for hormone receptor-positive HER2-negative locally advanced/metastatic breast cancer in women aged 70 years and older – final results of the endocrine-sensitive cohort in the French prospective non-interventional PalomAGE study
AU - E. Carola
AU - P. Caillet
AU - C. Falandry
AU - L. Tassy
AU - E. Paillaud
AU - M. Pulido
AU - G. Rochette de Lempdes
AU - M. Bringuier
AU - N. Jovenin
AU - A. Boudrant
AU - J. Grosjean
AU - C. Chakiba-Brugere
AU - O. Guillem
AU - A C Hardy Bessard
AU - H. Orfeuvre
AU - E. Legouffe
AU - Y. Brault
AU - C. Chen
AU - A. Coumert
AU - M. Decrop
AU - F. Bouteiller
AU - E. Brain
PY - 2026
DA - 2026/11/16
JO - The Breast
DO - 10.1016/j.breast.2026.104879
UR - https://hal.science/hal-05866217v1
AB - Background Breast cancer (BC) is the most commonly diagnosed cancer among women, with 30% of cases occurring at age ≥70 years (70+). Because patients 70+ are underrepresented in BC clinical trials, real-world data may help fill treatment knowledge gaps for this population. Patients and methods PalomAGE is a French observational, multicentre, prospective study assessing the real-world feasibility of ET + palbociclib in women 70+ with hormonal receptor-positive/HER2-negative (/HER+/HER2-) locally advanced/metastatic BC (ABC). The primary endpoint was palbociclib permanent discontinuation rate at 18 months. Secondary endpoints included time to treatment failure (TTF), real-world progression-free survival (rwPFS), health-related quality of life (HRQoL) and geriatric status (G8 and G-CODE). Here, we report results from the endocrine-sensitive cohort, using ET + palbociclib as first-line treatment. Results From October 2018 through December 2020, 412 patients were enrolled. Of these, 382 received ≥1 cycle of palbociclib. With a median follow-up of 25.2 months, the 18-month palbociclib permanent discontinuation rate was 41%. The median TTF and rwPFS were 23.0 and 30.4 months, respectively. Palbociclib dose reduction and permanent discontinuation due to adverse events occurred in 35% and 11% of patients, respectively. There were no new safety signals and HRQoL remained stable throughout treatment. An altered G8 (≤14/17) at baseline was an independent factor for palbociclib discontinuation by multivariate analysis. Conclusion This analysis showed that first-line ET + palbociclib is feasible, well-tolerated and maintains HRQoL in women 70+ with endocrine-sensitive HR+/HER2- ABC, consistent with results from the general adult population. The G8 tool may help identify vulnerable older patients needing further geriatric assessment.
SN - 0960-9776
SN - 1532-3080
ER -